Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma
about
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsDNA methylation biomarkers: cancer and beyondThe MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomideMGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.Genome-wide methylation analyses in glioblastoma multiforme.Management of high-grade gliomas in the pediatric patient: Past, present, and future.Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.MGMT testing allows for personalised therapy in the temozolomide era.European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS: an EQA study.Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.Intratumoral Heterogeneity of the Epigenome.Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.Quantitative DNA methylation analysis improves epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.Promoter hypermethylation and suppression of glutathione peroxidase 3 are associated with inflammatory breast carcinogenesis.MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Cancer genomics identifies disrupted epigenetic genes.MGMT testing--the challenges for biomarker-based glioma treatment.Molecular profiling of gliomas: potential therapeutic implications.Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.The Effect of Molecular Diagnostics on the Treatment of Glioma.Using nanobiotechnology to increase the prevalence of epigenotyping assays in precision medicine.Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis.Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.Management of Elderly Patients with Glioblastoma after CE.6.The methylation of a panel of genes differentiates low-grade from high-grade gliomas.Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.MGMT promoter methylation in non-neoplastic brain.
P2860
Q26795767-AA48A613-27CB-46B2-9557-282A83AEA19DQ26996421-01D8020E-0FDE-4DDB-A589-C35ADC8200FAQ27853156-85E9C740-7761-4B0B-8980-C9102EE847B7Q34166477-1F41088A-9B73-42C1-A9D0-425307899582Q34625644-39EFA7C7-2B5F-4184-A36A-AA73920C9876Q35079153-24ACC30C-79D2-4773-8182-7F25EF4CBF99Q35107175-8D9FFD2C-1C36-4EE7-A561-33031BBD0252Q35206259-D0C75B7D-9A48-4572-A421-B514F396FB45Q35741879-D55C204F-07A6-4D31-968D-8FDFB1BE03EBQ35827916-0FDD1337-3266-4385-AB6B-A0066665FD0FQ36338177-5AFAD8B9-884B-452D-BD29-866DF1336D41Q36500074-2D909BAD-CD49-40B7-A1F6-E6F648EA9FC5Q36552798-9B0DD43D-1D57-4096-B95C-427049A73260Q36854908-5BD0E400-86B9-4CA6-A858-55E369B1C7D6Q37081022-44E387D3-DC35-4901-8A3B-020753A957C8Q37221207-6BBA1C02-65E3-446C-83E8-2DBAE9C733E9Q37478188-19647E15-1F9C-4864-95A5-69AFCCDE02B3Q37502558-5346826B-2AAC-4208-BD0F-3A702DE8B261Q37526270-021568EB-40F9-4DF0-AA12-433218F9FD0CQ37641708-2B9B3BF7-CE65-45BF-AA2B-4E43C35CEE90Q37693777-F77E1502-E069-4556-8B5B-EDB64F026BB0Q38044236-9DB40115-A133-4101-9D03-A0EA1B121B31Q38081221-7F727144-675A-4B15-A66E-48BA67A68969Q38108186-944B4F90-258E-4A97-A8FE-555B050C71B2Q38150651-FE0CE169-B618-46F5-BA6A-2D58F5028CECQ38218848-CDECDFDB-B3C2-452A-A366-226BBEEF881EQ38539422-840E98BB-51B9-47D1-909A-F5D9235AAF40Q38675705-82614571-3028-4EA3-8B1F-85DA19D5AB18Q38743781-43E95516-76BE-43B0-B08F-38084155468EQ38820366-B4DE21C1-6166-4321-BFFC-92F809E22A3BQ39247768-972F0DA2-F143-48F0-BA67-63E46CC7FB4CQ39266259-CF817B64-B702-4502-AF5C-658A4BA357EFQ39600412-319CE677-A49A-4C62-8A66-C2EB0208EF2AQ40927284-F6611A7A-711B-48F5-8285-89967EF3EEABQ41009177-47E8B632-9A24-40DA-85A0-B90D1839E0DEQ41598861-3BBC1597-287F-4F95-9B64-1DA50B9AE610Q41618968-701287C5-3AD8-46B4-BFB4-412DC767ABB6Q41870675-424C29F4-A9EB-4CD5-8DD7-7A4ACDCCF285Q42364418-020C27B1-383C-496D-96C9-A8DA006469E7Q44440342-494E6FCB-E0CE-4158-8541-72442A6EB3B9
P2860
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@ast
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@en
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@nl
type
label
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@ast
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@en
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@nl
prefLabel
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@ast
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@en
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@nl
P2093
P2860
P50
P3181
P1433
P1476
Prognostic value of three diff ...... n newly diagnosed glioblastoma
@en
P2093
Arne Christians
Axel Benner
Christian Hartmann
Jochen Meyer
Markus Weiler
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0033449
P407
P577
2012-01-01T00:00:00Z